Intestinal Failure-Associated Liver Disease

checkorphan

Synonyms

IFALD, Parenteral Nutrition-Associated Liver Disease, PNALD,

Overview

Intestinal failure-associated liver disease (IFALD) is a serious, often progressive liver condition affecting patients on long-term parenteral nutrition (PN), commonly due to short bowel syndrome. It presents as a spectrum from steatosis and cholestasis to fibrosis, cirrhosis, and liver failure, with high prevalence in neonates (up to 85%).

Symptoms

Intestinal Failure-Associated Liver Disease (IFALD) symptoms include persistent jaundice, dark urine, pale stools, fatigue, nausea, and right-sided abdominal pain, often stemming from cholestasis or steatosis due to long-term parenteral nutrition. Advanced cases may present with ascites (swollen belly), confusion, or signs of portal hypertension.

Causes

Intestinal Failure-Associated Liver Disease (IFALD) is a multifactorial condition caused by long-term parenteral nutrition (PN), specifically soybean-based lipid emulsions, caloric overload, and nutrient deficiencies (choline, taurine). Key drivers include gut microbiota dysbiosis, bacterial translocation due to increased intestinal permeability, central line-associated infections (CLABSI), and disrupted bile acid metabolism.

Prevention

Prevention focuses on minimizing long-term parenteral nutrition (PN), reducing soybean-based lipid emulsions, and promoting early enteral feeding. Key strategies include using mixed-oil or fish-oil lipid emulsions, preventing sepsis through catheter care, cyclic PN, and enhancing intestinal adaptation to reduce liver damage

Diagnosis

Diagnosis relies on identifying persistent liver function test (LFT) abnormalities, specifically elevated ALP, GGT, or bilirubin (>1.5–3x ULN for >6 weeks in children or >6 months in adults), in patients receiving long-term parenteral nutrition (PN). It requires excluding other liver diseases (viral, autoimmune, biliary obstruction) and establishing a temporal link with PN.

Prognosis

Prognosis is variable, ranging from reversible liver dysfunction to severe, potentially fatal cirrhosis if untreated. While historically poor, specialized intestinal rehabilitation can achieve high rates of reversal (up to 99% in some cases). Advanced stages (fibrosis/cirrhosis) carry high mortality, often necessitating transplantation.

Treatment

Treatment focuses on reducing Parenteral Nutrition (PN) dependency through early enteral feeding, cycling PN, optimizing lipid emulsions (e.g., using fish-oil-based lipids), and managing sepsis. Key strategies include using Ursodeoxycholic acid (UDCA), avoiding nutrient deficiencies, and, in severe, irreversible cases, liver/intestinal transplantation.